Skip to main content
Medical information Clinical review pending

Genetic Testing

WISP3 Gene Arthropathy Progressive Pseudorheumatoid of Childhood Genetic Test

Genetic test for mutations in the WISP3 gene, associated with progressive pseudorheumatoid arthropathy in children. Helps identify genetic predispositions related to osteology and dermatology.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube), Extracted DNA, or One drop of blood on an FTA card.
Results
Approximately 3 to 4 weeks. Confirm with the laboratory before booking.
Preparation
Provide a complete clinical history. A genetic counseling session, including pedigree chart creation, is recommended before testing.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the WISP3 Gene Arthropathy Progressive Pseudorheumatoid of Childhood Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Children presenting with symptoms of joint pain or swelling.
  • ✓Individuals with a family history of pseudorheumatoid arthropathy.
  • ✓Patients with clinical features suggestive of related osteology, dermatology, or immunology disorders.
  • ✓Family members of individuals diagnosed with WISP3-related conditions.
02

In plain language

What this test helps you understand

Identifies genetic mutations in the WISP3 gene associated with progressive pseudorheumatoid arthropathy in childhood. Aids in diagnosis, treatment planning, and genetic counseling for affected individuals and families.
The WISP3 Gene Arthropathy Progressive Pseudorheumatoid of Childhood NGS Genetic DNA Test is a genetic analysis used to help diagnose and understand genetic disorders related to osteology and dermatology. This test uses Next Generation Sequencing (NGS) technology to examine the WISP3 gene. Variations in this gene are linked to progressive pseudorheumatoid arthropathy in children. Identifying these genetic changes can support early diagnosis, guide treatment decisions, and inform family counseling.

This test specifically looks for mutations within the WISP3 gene. Detecting these genetic variations provides important information about an individual's genetic makeup and potential risk for developing certain conditions.

This test may be considered for individuals experiencing symptoms like joint pain or swelling, those with a family history of pseudorheumatoid arthropathy, or patients whose clinical presentation suggests related osteology, dermatology, or immunology disorders.

Benefits of this test include early identification of genetic predispositions, support for informed treatment decisions, guidance for family planning and risk assessment, and access to appropriate care and management strategies.

It is important to discuss your results with a healthcare professional or genetic counselor. They can help interpret the findings and explain what they mean for your health and your family.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationProvide a complete clinical history. A genetic counseling session, including pedigree chart creation, is recommended before testing.
SampleBlood sample (EDTA tube), Extracted DNA, or One drop of blood on an FTA card.
MethodologyNext Generation Sequencing (NGS) analysis of the WISP3 gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test analyzes specific regions of the WISP3 gene. It may not detect all possible mutations. Results should be interpreted in the context of clinical findings and family history. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

This is a rare genetic disorder primarily affecting children, characterized by joint inflammation, pain, and swelling, often resembling juvenile rheumatoid arthritis.
Testing is typically recommended for children with symptoms suggestive of the condition, individuals with a family history, or those with related clinical features.
The test involves analyzing a sample of your blood or DNA to look for specific genetic changes (mutations) in the WISP3 gene.
Results should be discussed with a healthcare professional or genetic counselor who can explain the findings in the context of your clinical picture and family history.
Identifying a mutation indicates a predisposition, but it does not always guarantee the condition will develop. Clinical factors also play a role.
Insurance coverage varies. Please check with your insurance provider regarding coverage for genetic testing.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp